George W. Sledge

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 29 papers. Top paper: “Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx”.

Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx

Journal of Clinical Oncology(2020)10.1200/jco.19.01866

N/A

3.5DataRank · unranked

102 citations

Robert J. Gray, Joseph A. Sparano, Timothy J. Whelan, Sofia F. Garcia, Betina R. Yanez +14 more

Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer

npj Breast Cancer(2022)10.1038/s41523-021-00376-9

N/A

1.3DataRank · unranked

27 citations

Anne O’Neill, Noah Graham, Donald W. Northfelt, Chau T. Dang, Antonio C. Wolff +3 more

Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa148

N/A

0.714DataRank · unranked

116 citations

Robert J. Gray, Della Makower, Amir Faghih, Daniel F. Hayes, Charles E. Geyer +23 more

Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer

Nature Communications(2023)10.1038/s41467-023-37636-0

N/A

0.553DataRank · unranked

39 citations

Victor Ritter, Natasha Purington, Karen Andrade, Summer S. Han, Mina Liu +10 more

Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG‐ACRIN TAILORx trial

Cancer(2021)10.1002/cncr.33527

N/A

0.510DataRank · unranked

29 citations

Robert J. Gray, Joseph A. Sparano, Betina R. Yanez, Sofia F. Garcia, Lava Timsina +5 more

Pan-Cancer Interrogation of B7-H3 ( CD276 ) as an Actionable Therapeutic Target Across Human Malignancies

Cancer Research Communications(2024)10.1158/2767-9764.crc-23-0546

N/A

0.500DataRank · unranked

27 citations

John R. Lozada, Nicholas A. Zorko, Andrew Elliott, Allison Makovec, Milan Radovich +18 more

Quality of Life Following Receipt of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node–Positive and High-Risk Lymph Node–Negative Breast Cancer

JAMA Network Open(2022)10.1001/jamanetworkopen.2022.0254

N/A

0.488DataRank · unranked

7 citations

Anne O’Neill, Karen Sepucha, Kathy D. Miller, Chau T. Dang, Donald W. Northfelt +4 more

Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes

Prostate Cancer and Prostatic Diseases(2024)10.1038/s41391-024-00797-0

N/A

0.477DataRank · unranked

23 citations

Allison Makovec, Andrew Elliott, Samuel Kellen, John R. Lozada, Ali T. Arafa +19 more

Loss of Pip4k2c confers liver-metastatic organotropism through insulin-dependent PI3K-AKT pathway activation

Nature Cancer(2024)10.1038/s43018-023-00704-x

N/A

0.464DataRank · unranked

21 citations

Tyler J. Aprati, Wei-Yu Chi, Johannes C. Melms, Clemens Hug, Stephanie H. Davis +40 more

Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy

Cancer Research Communications(2024)10.1158/2767-9764.crc-24-0321

N/A

0.375DataRank · unranked

6 citations

Gregory Dyson, Jennifer R. Ribeiro, Joanne Xiu, Kelsey Poorman, Hirva Mamdani +16 more

Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profiling

npj Breast Cancer(2025)10.1038/s41523-025-00868-y

N/A

0.373DataRank · unranked

11 citations

Joanne Xiu, Reshma Mahtani, Ana C. Sandoval Leon, Funda Meric‐Bernstam, Jennifer R. Ribeiro +8 more

Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient‐reported outcomes substudy

Cancer(2021)10.1002/cncr.33939

N/A

0.292DataRank · unranked

6 citations

Robert J. Gray, Joseph A. Sparano, Amyé Tevaarwerk, Ruth C. Carlos, Betina R. Yanez +6 more

Cytochrome P450 Oxidoreductase ( POR ) Associated with Severe Paclitaxel-Induced Peripheral Neuropathy in Patients of European Ancestry from ECOG-ACRIN E5103

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2431

N/A

0.269DataRank · unranked

5 citations

Guanglong Jiang, Santosh Philips, Laura Gardner, Gloria Xue, Erica Cantor +10 more

Social determinants of health, genetic ancestry, and mortality in ECOG-ACRIN E5103.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.6527

N/A

0.251DataRank · unranked

3 citations

Anne O’Neill, Kathy D. Miller, Bryan P. Schneider, Ann H. Partridge, Lava Timsina +4 more

Identifying distinct prognostic and predictive contributions of tumor epithelium versus tumor microenvironment in colorectal cancer

BMC Cancer(2025)10.1186/s12885-025-13829-2

N/A

0.241DataRank · unranked

4 citations

Michael Nebozhyn, Michael J. Schell, Nishant Gandhi, Lance Pflieger, Andrey Loboda +14 more

A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07417-4

N/A

0.215DataRank · unranked

3 citations

Anne O’Neill, Ingrid A. Mayer, Carlos L. Arteaga, Ximing J. Yang, Lynne I. Wagner +17 more

Pan-cancer analysis of natural killer (NK) cell infiltration in human malignancies: Molecular features and clinical implications.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2563

N/A

0.208DataRank · unranked

3 citations

Justin H. Hwang, John R. Lozada, Hilary Seifert, Andrew Elliott, Milan Radovich +8 more

CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07519-z

N/A

0.174DataRank · unranked

2 citations

Anne O’Neill, Bryan P. Schneider, Todd C. Skaar, Minetta C. Liu, Caroline Lohrisch +9 more

Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer in the ECOG-ACRIN 5103 trial.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.520

N/A

0.165DataRank · unranked

2 citations

Anne O’Neill, Noah Graham, Donald W. Northfelt, Chau T. Dang, Antonio C. Wolff +3 more

EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition

Oncogene(2025)10.1038/s41388-025-03634-3

N/A

0.165DataRank · unranked

2 citations

Donna Voeller, Yonit A. Addissie, Sachin Kumar Deshmukh, Sharon Wu, Maryam B. Lustberg +7 more

A 20-feature radiomic signature of triple-negative breast cancer identifies patients at high risk of death

npj Breast Cancer(2025)10.1038/s41523-025-00790-3

N/A

0.165DataRank · unranked

2 citations

Yuanning Zheng, A. Mantz, Ryle Zhou, Andrew Kozlov, Wendy B. DeMartini +15 more

Early discontinuation to adjuvant endocrine therapy in the ECOG-ACRIN TAILORx Trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7004

N/A

0.104DataRank · unranked

1 citations

Robert J. Gray, Joseph A. Sparano, Ruth C. Carlos, Gelareh Sadigh, Sofia F. Garcia +6 more

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

Digital Commons@Becker (Washington University School of Medicine)(2020)10.17615/6e7v-pv95

N/A

0.104DataRank · unranked

1 citations

Tracy Lively, John A. Olson, Robert J. Gray, Virginia Kaklamani, Della Makower +26 more

EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.06.03.657674

N/A

0DataRank · unranked

0 citations

Donna Voeller, Yonit A. Addissie, Sachin Kumar Deshmukh, Sharon Wu, Maryam B. Lustberg +7 more

Impact of African ancestry on the relationship between body mass index and survival in an early‐stage breast cancer trial (ECOG‐ACRIN E5103)

Cancer(2022)10.1002/cncr.34173

N/A

0DataRank · unranked

13 citations

Guanglong Jiang, Fei Shen, Kathy D. Miller, George W. Sledge, Bryan P. Schneider +1 more

Variation in FOLFOX, FOLFIRI, and FOLFOXIRI effects on CD8+ T cell and PDL1 levels in MSS CRC patients.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3526

N/A

0DataRank · unranked

0 citations

Andrew Elliott, Marzia Capelletti, Emil Lou, John L. Marshall, Heinz‐Josef Lenz +10 more

Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN 5103 and BEATRICE

British Journal of Cancer(2024)10.1038/s41416-024-02602-0

N/A

0DataRank · unranked

0 citations

Guanglong Jiang, Santosh Philips, Erica Cantor, Laura Gardner, Gloria Xue +9 more

A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

Research Square(2024)10.21203/rs.3.rs-4295044/v1

N/A

0DataRank · unranked

0 citations

Anne O’Neill, Ingrid A. Mayer, Carlos L. Arteaga, Ximing J. Yang, Lynne I. Wagner +17 more

Interferon signaling and outcomes in triple-negative breast cancer (TNBC) in FinXX, CALGB 40603 (Alliance) and real-world clinico-genomic data.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.569

N/A

0DataRank · unranked

0 citations

Yi Liu, Sachin Kumar Deshmukh, Jodi M. Carter, Heikki Joensuu, Roberto A. Leon‐Ferre +15 more